Overview

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.

Phase:

Phase 3

Details

Lead Sponsor:

AcelRx Pharmaceuticals, Inc.

Treatments:

Sufentanil